BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 34146196)

  • 1. Second-line treatments for Advanced Hepatocellular Carcinoma: A Systematic Review and Bayesian Network Meta-analysis.
    Solimando AG; Susca N; Argentiero A; Brunetti O; Leone P; De Re V; Fasano R; Krebs M; Petracci E; Azzali I; Nanni O; Silvestris N; Vacca A; Racanelli V
    Clin Exp Med; 2022 Feb; 22(1):65-74. PubMed ID: 34146196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Therapy and Sequencing Options in Advanced Hepatocellular Carcinoma: A Systematic Review and Network Meta-analysis.
    Sonbol MB; Riaz IB; Naqvi SAA; Almquist DR; Mina S; Almasri J; Shah S; Almader-Douglas D; Uson Junior PLS; Mahipal A; Ma WW; Jin Z; Mody K; Starr J; Borad MJ; Ahn DH; Murad MH; Bekaii-Saab T
    JAMA Oncol; 2020 Dec; 6(12):e204930. PubMed ID: 33090186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line Treatments of Advanced Hepatocellular Carcinoma: Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Bakouny Z; Assi T; El Rassy E; Nasr F
    J Clin Gastroenterol; 2019 Apr; 53(4):251-261. PubMed ID: 30575632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
    Kelley RK; Mollon P; Blanc JF; Daniele B; Yau T; Cheng AL; Valcheva V; Marteau F; Guerra I; Abou-Alfa GK
    Adv Ther; 2020 Jun; 37(6):2678-2695. PubMed ID: 32424805
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety for second-line treatment with ramucirumab, regorafenib, and cabozantinib in patients with advanced hepatocellular carcinoma progressed on sorafenib treatment: A network meta-analysis.
    Chen J; Wang J; Xie F
    Medicine (Baltimore); 2021 Sep; 100(38):e27013. PubMed ID: 34559096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A systematic review and network meta-analysis of second-line therapy in hepatocellular carcinoma.
    Delos Santos S; Udayakumar S; Nguyen A; Ko YJ; Berry S; Doherty M; Chan KKW
    Curr Oncol; 2020 Dec; 27(6):300-306. PubMed ID: 33380861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A network meta-analysis of efficacy and safety of first-line and second-line therapies for the management of metastatic renal cell carcinoma.
    Heo JH; Park C; Ghosh S; Park SK; Zivkovic M; Rascati KL
    J Clin Pharm Ther; 2021 Feb; 46(1):35-49. PubMed ID: 33112003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regorafenib versus cabozantinb as second-line treatment after sorafenib for unresectable hepatocellular carcinoma: matching-adjusted indirect comparison analysis.
    Casadei-Gardini A; Rimassa L; Rimini M; Yoo C; Ryoo BY; Lonardi S; Masi G; Kim HD; Vivaldi C; Ryu MH; Rizzato MD; Salani F; Bang Y; Pellino A; Catanese S; Burgio V; Cascinu S; Cucchetti A
    J Cancer Res Clin Oncol; 2021 Dec; 147(12):3665-3671. PubMed ID: 33745079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
    Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
    PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial.
    Kudo M; Okusaka T; Motomura K; Ohno I; Morimoto M; Seo S; Wada Y; Sato S; Yamashita T; Furukawa M; Aramaki T; Nadano S; Ohkawa K; Fujii H; Kudo T; Furuse J; Takai H; Homma G; Yoshikawa R; Zhu AX
    J Gastroenterol; 2020 Jun; 55(6):627-639. PubMed ID: 32107609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing the efficacy and safety of second-line therapies for advanced hepatocellular carcinoma: a network meta-analysis of phase III trials.
    Wang D; Yang X; Lin J; Bai Y; Long J; Yang X; Seery S; Zhao H
    Therap Adv Gastroenterol; 2020; 13():1756284820932483. PubMed ID: 32636928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Second-line treatment of hepatocellular carcinoma after sorafenib: Characterizing treatments used over the past 10 years and real-world eligibility for cabozantinib, regorafenib, and ramucirumab.
    Fung AS; Tam VC; Meyers DE; Sim HW; Knox JJ; Zaborska V; Davies J; Ko YJ; Batuyong E; Samawi H; Cheung WY; Lee-Ying R
    Cancer Med; 2020 Jul; 9(13):4640-4647. PubMed ID: 32378799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis.
    Park J; Cho J; Lim JH; Lee MH; Kim J
    Target Oncol; 2019 Aug; 14(4):395-403. PubMed ID: 31290003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selection of first-line systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Han Y; Zhi WH; Xu F; Zhang CB; Huang XQ; Luo JF
    World J Gastroenterol; 2021 May; 27(19):2415-2433. PubMed ID: 34040331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial.
    Kelley RK; Ryoo BY; Merle P; Park JW; Bolondi L; Chan SL; Lim HY; Baron AD; Parnis F; Knox J; Cattan S; Yau T; Lougheed JC; Milwee S; El-Khoueiry AB; Cheng AL; Meyer T; Abou-Alfa GK
    ESMO Open; 2020 Aug; 5(4):. PubMed ID: 32847838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Cabozantinib and Ramucirumab After Sorafenib for Patients with Hepatocellular Carcinoma and Alpha-fetoprotein ≥ 400 ng/mL: A Matching-Adjusted Indirect Comparison.
    Trojan J; Mollon P; Daniele B; Marteau F; Martín L; Li Y; Xu Q; Piscaglia F; Zaucha R; Sarker D; Lim HY; Venerito M
    Adv Ther; 2021 May; 38(5):2472-2490. PubMed ID: 33822328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-Effectiveness of Cabozantinib in the Second-Line Treatment of Advanced Hepatocellular Carcinoma.
    Soto-Perez-de-Celis E; Aguiar PN; Cordón ML; Chavarri-Guerra Y; Lopes GL
    J Natl Compr Canc Netw; 2019 Jun; 17(6):669-675. PubMed ID: 31200357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An updated meta-analysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.
    Peng S; Zhao Y; Xu F; Jia C; Xu Y; Dai C
    PLoS One; 2014; 9(12):e112530. PubMed ID: 25460347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targeted therapy and immunotherapy in advanced hepatocellular carcinoma: a systematic review and Bayesian network meta-analysis based on randomized controlled trials.
    Zhang YL; Cui XJ; Xing H; Ning HF; Dong P; Wang GZ
    Ann Med; 2023; 55(2):2242384. PubMed ID: 37557186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.